Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - \<70.~2. Patients with advanced ovarian, fallopian or primary peritoneal cancer in second or later complete remission, or untreated or refractory relapse, defined as relapse within 6 months of prior platinum treatment or lack of response to salvage treatment.~3. No evidence of small bowel obstruction, as determined by CT scan of the abdomen and pelvis with oral and rectal contrast, within 30 days before the initiation of study treatment.~4. Adequate renal glomerular and tubular function, as defined by estimated serum creatinine clearance \>=60 ml/min, and urinary protein excretion \<=500 mg/day.~5. Adequate hepatic function, as defined by serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) \<=3 \* upper limit of normal (ULN); serum bilirubin and alkaline phosphatase \<=2 \* ULN or considered not clinically significant.~6. Adequate pulmonary function with Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) \>=50% of predicted, corrected for volume or hemoglobin.~7. Adequate cardiac function with left ventricular ejection fraction \>=45%. No uncontrolled arrhythmias or symptomatic cardiac disease.~8. Zubrod performance status \<2.~Exclusion Criteria:~1. Failure to collect more than 3 \* 10e6 CD34+ stem cells/kg body weight~2. Patients with unresolved grade 3 or greater non-hematologic toxicity from previous therapy. Patients with grade 2 toxicity will be eligible at the discretion of the principal investigator.~3. Major surgery within 30 days before the initiation of study treatment~4. Radiotherapy within 21 days prior to initiation of study treatment~5. Patients with active Central Nervous System (CNS) disease.~6. Evidence of acute or chronic active hepatitis or cirrhosis. If positive hepatitis serology, discuss with Principal Investigator and consider liver biopsy.~7. Uncontrolled infection, including HIV or HTLV-1 infection.~8. Aspirin (\> 325 mg/day) use within 10 days before initiation of study treatment.~9. Ongoing uncontrolled hypertension (\>140/90 mm Hg on medication).~10. Non-healing wound or significant traumatic injury within 30 days before the initiation of study treatment~11. Previous autologous or allogeneic stem cell transplant during the past year.~12. Positive Beta HCG test in a woman with child-bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + High-Dose Chemotherapy (Type: EXPERIMENTAL): Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m\^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m\^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m\^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues